Adamo Joan E, Meseda Clement A, Weir Jerry P, Merchlinsky Michael J
Laboratory of DNA Viruses, Center for Biologics Evaluation and Research (CBER), US Food and Drug Administration (FDA), Bethesda, MD 20892, USA.
J Gen Virol. 2009 Nov;90(Pt 11):2604-2608. doi: 10.1099/vir.0.008474-0. Epub 2009 Jul 8.
Vaccination with Dryvax elicits a broad humoral response against many viral proteins. Human vaccinia immune globulin was used to screen the secreted proteins from cells infected with Dryvax or the candidate smallpox vaccine LC16m8 to determine whether the protective humoral response included antibodies against secreted viral proteins. Many proteins were detected, with the primary band corresponding to a band of 28 or 30 kDa in cells infected with Dryvax or LC16m8, respectively. This was identified as the vaccinia virus complement protein (VCP), which migrated more slowly in LC16m8-infected cells due to post-translational glycosylation. Vaccinia virus deleted in VCP, vVCPko, protected mice from a lethal intranasal challenge of vaccinia Western Reserve strain. Mice vaccinated with purified VCP demonstrated a strong humoral response, but were not protected against a moderate lethal challenge of vaccinia virus, suggesting that the humoral response against VCP is not critical for protection.
接种Dryvax疫苗可引发针对多种病毒蛋白的广泛体液免疫反应。用人痘苗免疫球蛋白筛选感染Dryvax或候选天花疫苗LC16m8的细胞所分泌的蛋白质，以确定保护性体液免疫反应是否包括针对分泌型病毒蛋白的抗体。检测到许多蛋白质，主要条带分别对应于感染Dryvax或LC16m8的细胞中28 kDa或30 kDa的条带。这被鉴定为痘苗病毒补体蛋白（VCP），由于翻译后糖基化，其在感染LC16m8的细胞中迁移较慢。缺失VCP的痘苗病毒vVCPko可保护小鼠免受痘苗病毒西储备株致命性鼻内攻击。用纯化的VCP接种的小鼠表现出强烈的体液免疫反应，但不能抵御痘苗病毒的中度致死性攻击，这表明针对VCP的体液免疫反应对保护作用并不关键。
